AMD 3329

Drug Profile

AMD 3329

Alternative Names: AMD-3329

Latest Information Update: 11 Dec 2006

Price : $50

At a glance

  • Originator AnorMED; Rega Institute for Medical Research
  • Class Antivirals; Heterocyclic compounds
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 11 Nov 1999 Preclinical development for HIV infections treatment in Canada (unspecified route)
  • 11 Nov 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top